Avalanche Journal: Assessing potential options for Colorado’s No. 24 pick, an “unreal asset” – The Cannabist

Chris MacFarland could use another couple of days at the NHL draft like he experienced a year ago.

The Colorado Avalanche general manager won’t have some of the same tools available to him to help reshape his current roster, but MacFarland and his club could certainly use an impact prospect, some present help for the NHL team, or both.

Colorado has the No. 24 selection at the 2024 NHL draft, which next weekend in Las Vegas. The Avs currently don’t have another pick until the fourth round, at No. 121.

Read the rest of this story on TheKnow.DenverPost.com.

Landmark CRISPR approval; Why don’t investors like Verve’s base editing data?; Janet Woodcock to retire; Late Friday IPO filing; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit

November 19, 2023

Developing a prognostic model for bladder urothelial cancer using oxidative stress signatures

A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 3,

February 28, 2024

The decline and fall of elite multispecialty medical groups

The failure of Geisinger Health System, which lost $842 million in 2022 and disappeared into a new Kaiser subsidiary called Risant, sent shockwaves through the

January 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.